
    
      Patient who are electrically cardioverted require 1 month of anticoagulation (blood thinner).
      Rivaroxaban a Xa-inhibitor has been shown to be non-inferior to Warfarin (Vit K antagonist)
      the current standard of care in many treatment areas. Rivaroxaban will be compared to
      Warfarin historical control group studying the safety and efficacy in electrically
      cardioverted patients.
    
  